OSE Immunotherapeutics S.A.
OSE
Rank in Stocks
#23159
Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating... Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline features Tedopi, which is currently in Phase III clinical trials for non-small cell lung cancer, with further Phase II investigations ongoing for pancreatic and ovarian cancers. For infectious diseases, they are developing CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus. In oncology, their portfolio also includes BI 765063, in Phase I for solid tumors, and BiCKI, an innovative bispecific checkpoint inhibitor platform. BiCKI is engineered to counteract cancer's primary and secondary resistance mechanisms by targeting PD-1 alongside other novel pathways. Addressing autoimmune and inflammatory conditions, OSE Immunotherapeutics is progressing OSE-127, a humanized monoclonal antibody in Phase II trials for both ulcerative colitis and Sjögren's Syndrome. FR104 is undergoing Phase I development for rheumatoid arthritis, while OSE-230, an agonist antibody against ChemR23, aims to resolve chronic inflammation. The company maintains strategic collaborations and partnerships with organizations such as GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. OSE Immunotherapeutics S.A. was formerly known as OSE Pharma SA until its name change in May 2016.
Share Price
$1.91
Last synced: 2026-11-09
Market Cap
$44.95M
Change (1 day)
0.50%
Change (1 year)
-71.12%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade OSE Immunotherapeutics S.A. (OSE)
Category
Healthcare
Operating Margin for OSE Immunotherapeutics S.A. (OSE)
Operating Margin as of November 2026 TTM: -1,835.01%
According to OSE Immunotherapeutics S.A.'s latest financial reports, its current operating margin (TTM) is -1,835.01%. At the end of 2025 the company had an operating margin of -1,835.01%.
Operating Margin history for OSE Immunotherapeutics S.A. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,835.01% | 0.00% |
| 2025 | -1,835.01% | -3,031.79% |
| 2024 | 62.59% | -106.06% |
| 2023 | -1,032.15% | 922.44% |
| 2022 | -100.95% | 59.73% |
| 2021 | -63.20% | -65.33% |
| 2020 | -182.27% | 3,114.64% |
| 2019 | -5.67% | -128.61% |
| 2018 | 19.82% | -110.49% |
| 2017 | -188.96% | -104.14% |
| 2016 | 4,568.93% | -103.37% |
| 2015 | -135,500.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.02% |
US
|
|
| -149.01% | -99.92% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.02% |
BE
|
|
| 29.35% | -100.02% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about OSE Immunotherapeutics S.A.'s operating margin
What is OSE Immunotherapeutics S.A.'s operating margin?
OSE Immunotherapeutics S.A.'s operating margin is -1,835.01%, as of Nov 2026.
What was OSE Immunotherapeutics S.A.'s operating margin in 2025?
In 2025, OSE Immunotherapeutics S.A.'s operating margin was -1,835.01%, compared with 62.59% in 2024.
How has OSE Immunotherapeutics S.A.'s operating margin changed since 2020?
From 2020 to 2025, OSE Immunotherapeutics S.A.'s operating margin was highest in 2024 (62.59%) and lowest in 2025 (-1,835.01%).
How does OSE Immunotherapeutics S.A.'s operating margin compare with similar companies?
OSE Immunotherapeutics S.A.'s operating margin (-1,835.01%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.